News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Colon, Rectum & Anal Canal → cancer profile · × Clear filters
Global cancer statistics 2024: translating epidemiological trends into priorities for healthcare systems
A review in Nature Reviews Clinical Oncology discusses the global cancer burden using GLOBOCAN 2024 estimates: in 2024, 20.6 million people across 186 countries were diagnosed with cancer and 9.8 million died of it. Lung cancer remains the most common — 2.6 million new cases (12.8%) and 1.9 million deaths (19.1%) — ahead of female breast cancer (11.8% of cases), colorectal cancer (9.9%) and prosta…
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial
Adding ifebemtinib to garsorasib did NOT significantly improve response rate in a very small study: the randomised portion included just 36 patients with previously treated KRAS G12C-mutated metastatic colorectal cancer. The confirmed objective response rate was 38.9% (95% CI 17.3-64.3) versus 16.7% (95% CI 3.6-41.4) with garsorasib alone, but the 22.2-percentage-point difference had a confidence …
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial
In an organ-preservation strategy for rectal cancer, long-course chemoradiotherapy clearly outperformed short-course radiotherapy: at 12 months, survival free of total mesorectal excision was 78.5% (95% CI 72.4-85.1) versus 60.6% (53.6-68.4). The international phase 2/3 STAR-TREC trial enrolled 409 patients with early-stage and intermediate-stage rectal cancer, randomised to three arms: long-cours…
Spatial multi-omics landscape of colorectal cancer macro- and micrometastases
Integrated spatial transcriptomic, genomic, and proteomic profiling of colorectal cancer metastases reveals early clonal divergence, stem-like cellular features, and immunosuppressive microenvironments characterized by T cell exhaustion already present at the micrometastasis stage. The study identifies a colorectal liver micrometastasis-specific six-gene signature (CLiMi) that correlates with mini…
Mapping micrometastatic seeds of relapse
Spatial multi-omics profiling of colorectal cancer micrometastases in matched primary tumors, liver, and lung metastases revealed that liver micrometastases represent an early-evolved, stem-like, immune-suppressed residual disease state. The study identified a six-gene recurrence signature linked to these micrometastatic seeds. This finding reframes liver micrometastases as a distinct biological e…
Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147)
A study published in the Journal of Clinical Oncology evaluated a tissue-free circulating tumor DNA (ctDNA) assay for predicting patient outcomes in the context of FOLFOX-based adjuvant chemotherapy for colon cancer, using data from the large phase III Alliance N0147 trial. The tissue-free approach is notable because it does not require prior tumor sequencing to design a personalized ctDNA panel, …
Emerging trends in the global burden of colorectal cancer
A comprehensive review published in Nature Reviews Clinical Oncology examines the shifting global epidemiology of colorectal cancer, which has historically been concentrated in Western, high-income countries but is now rising worldwide. The authors identify early-onset colorectal cancer, diagnosed before age 50, as the primary driver of this increase. Proposed risk factors include dietary and life…
Uncovering risk factors in the exposome for early-onset colorectal cancer
A new perspective published in Nature Medicine examines the alarming rise in early-onset colorectal cancer and the role of environmental exposures — collectively known as the exposome — in driving this trend. The authors highlight epigenetic signatures as a promising tool to identify which environmental factors are contributing to the increasing incidence of colorectal cancer among younger individ…
Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603
The Journal of Clinical Oncology has published the long-term results of JCOG0603, a landmark Japanese randomized Phase II/III trial evaluating whether adding adjuvant mFOLFOX6 chemotherapy after liver resection improves outcomes for patients with colorectal cancer liver metastases compared to surgery alone. This trial addresses a longstanding clinical question, as the role of adjuvant chemotherapy…
Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure
A study published in Nature Medicine has identified epigenetic signatures linking pesticide exposure — particularly the herbicide picloram — to early-onset colorectal cancer in patients diagnosed before age 50. Researchers compared exposome traits between early-onset CRC patients and those diagnosed at age 70 or older, using epigenetic markers as molecular records of cumulative environmental expos…